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Background: Neuropsychiatric symptoms such as psychosis are prevalent in patients with probable Alzheimer’s
disease (AD) and are associated with increased morbidity and mortality. Because these disabling symptoms are
generally not well tolerated by caregivers, patients with these symptoms tend to be institutionalized earlier than
patients without them. The identification of protective and risk factors for neuropsychiatric symptoms in AD would
facilitate the development of more specific treatments for these symptoms and thereby decrease morbidity and
mortality in AD. The E4 allele of the apolipoprotein E (APOE) gene is a well-documented risk factor for the
development of AD. However, genetic association studies of the APOE 4 allele and BPS in AD have produced
conflicting findings.
Methods: This study investigates the association between APOE and neuropsychiatric symptoms in a large sample
of clinically well-characterized subjects with probable AD (n=790) who were systematically evaluated using the
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) Behavioral Rating Scale for Dementia (BRSD).
Results: Our study found that hallucinations were significantly more likely to occur in subjects with no APOΕ4
alleles than in subjects with two Ε4 alleles (15% of subjects and 5% of subjects, respectively; p=.0066), whereas
there was no association between the occurrence of delusions, aberrant motor behavior, or agitation and the
number of Ε4 alleles. However, 94% of the subjects with hallucinations also had delusions (D+H).
Conclusion: These findings suggest that in AD the Ε4 allele is differentially associated with D+H but not delusions
alone. This is consistent with the hypothesis that distinct psychotic subphenotypes may be associated with the
APOE allele.
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Alzheimer’s disease (AD) is a neurodegenerative disorder
that is characterized by a decline in cognitive function,
most notably in the areas of short-term memory and
learning. Between 30% and 60% of patients who are
affected with AD also develop psychotic symptoms (i.e.,* Correspondence: dwt1@uw.edu
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reproduction in any medium, provided the orhallucinations or delusions) during the course of their
illness [1]. Psychotic symptoms in these patients are
associated with aggression, which results in earlier and
more frequent institutionalization compared to patients
who are free of psychotic symptoms [2,3]. Therefore, it
is critical to understand the genetic, environmental, and
medical factors that may increase the risk for developing
psychosis in patients with AD.
One well-known risk factor for AD, particularly for
late-onset AD (LOAD), that may increase the risk of
developing psychosis in patients with AD is the E4 alleleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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studies have investigated a possible association between
the APOE*4 allele and the presence of psychotic symp-
toms in AD (AD+P)[4], but these study findings have
been inconsistent: 9 studies reported a significant associ-
ation, whereas 17 studies found no relationship or were
otherwise inconclusive [1,4,5]. In this study, we system-
atically assessed 790 subjects with probable AD at base-
line to investigate whether a relationship exists between
the APOE*4 allele and four neuropsychiatric symptom
(BPS) domains: hallucinations, delusions, agitation, and
aberrant motor behavior.
Materials and methods
Subjects
All data for this study were obtained using protocols that
were approved by the institutional review board at the
University of Pittsburgh. The study initially included 812
patients from the University of Pittsburgh Alzheimer
Disease Research Center (ADRC) who met the National
Institute of Neurological and Communicative Disorders
and Stroke–Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) clinical criteria for
probable AD during the years 1992–2007. All subjects
followed University of Pittsburgh ADRC protocol by
participating in standardized neurological, psychiatric,
neuropsychological, and functional evaluations, includ-
ing the Mini-Mental State Examination (MMSE) and
the Clinical Dementia Rating (CDR) scale [6]. Demo-
graphic data collected during the initial visit included gen-
der, education, age and duration of illness. The MMSE
and CDR scores used in this study correspond to subject
visits that occurred within six months of the initial neuro-
psychiatric evaluation visit. All procedures were approved
by an institutional review board and written informed
consent was obtained from the patient for publication of
this report.
Neuropsychiatric symptom assessments
Neuropsychiatric symptoms were evaluated using the
1992 and 1996 versions of the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) Behavioral Rat-
ing Scale for Dementia (BRSD). The BRSD collects infor-
mation from informants on six domains that are designed
to quantify the severity of neuropsychiatric abnormalities
in demented subjects [7,8]. In this study, we used ratings
from the first assessment that was conducted with infor-
mants after subjects were initially diagnosed with probable
AD. We focused on three neuropsychiatric domains gen-
erated from the BRSD items: psychosis (12 items), agita-
tion (3 items), and aberrant motor behavior (2 items).
Given that previous studies have reported conflicting find-
ings concerning the relationship between the APOE ε4
allele and psychosis [1,4], we subdivided the psychosiscategory into two domains: hallucinations (2 items) and
delusions (10 items). Hallucinations were defined as sen-
sory perceptions that were not observed by others and
delusions were defined as fixed false beliefs. Agitation was
defined as uncooperative, verbally abusive, and physically
aggressive behavior. Aberrant motor behavior was defined
as restless, confused, or nonpurposeful activity. Neuro-
psychiatric symptoms that only occurred during an epi-
sode of delirium were not rated as present.
APOE genotyping
The APOE three-allelic polymorphism was screened by
PCR-based assay as previously described [9]. Genomic
DNA were amplified using a forward primer E1, 5’-GCGG
ACATGGAGGACGTG-3’ and a reverse primer E2, 5’-GG
CCTGGTACACTGCCAG-3’. The 177-nucleotide ampli-
fied product was digested directly with the restriction
enzyme HhaI. The digested DNA was separated on 8%
nondenaturing polyacrylamide gel in 1 X TBE buffer, fol-
lowed by staining with ethidium bromide solution. The
APOE polymorphism was then typed by visualization
under UV light.
Statistical analysis
Four neuropsychiatric domains were included in the ana-
lyses: hallucinations, delusions, agitation, and aberrant
motor behavior. These domains were modeled as dichot-
omous: subjects for whom informants reported one or
more items in a domain were classified as positive for that
domain, whereas subjects for whom informants reported
no occurrences of any item in a domain were classified as
negative for that domain. Descriptive statistics of demo-
graphics and the neuropsychiatric domains are presented
as mean and standard deviation (SD) for continuous vari-
ables and as frequency and percentage of group totals for
categorical variables.
Differences in continuous variables by categorical vari-
ables were assessed using analysis of variance (the two-
sample t-test for two-category variables), and associations
between categorical variables were assessed using the chi-
square test. Generalized linear regression with log link
and error modeled as Gaussian was used to estimate the
relative risk (RR) and 95% confidence intervals (CIs) of the
occurrence of at least one abnormal neuropsychiatric
symptom in a given domain according to the number of
APOE*4 alleles (treated as categorical, with “no alleles” as
the reference category) [10,11]. The model covariates were
gender, education, age at BRSD assessment, baseline
MMSE score, duration of illness, and baseline CDR score.
Age, education, duration of illness, and MMSE were mod-
eled as restricted cubic splines with three degrees of
freedom to account for potential nonlinear trends [11,12],
and CDR was modeled as categorical (0.5, 1, 2, 3+). If a
significant association between behavioral domain and
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analysis, modeling the number of APOE*4 alleles as
continuous was carried out to determine if a dose–re-
sponse effect was present. Confidence intervals were
obtained through the construction of likelihood profiles
for each parameter [13].
Classification of a domain as positive or negative was
not possible for cases where at least one item in that do-
main was missing and the remaining items were either
coded as 0 (i.e., the behavior or symptom was not present)
or were also missing. For these cases, the domain was
imputed to the median response of all individuals with
non-missing domain values. As a sensitivity analysis, a
second set of models was run to impute the missing do-
main values to the alternate values. For example, the hal-
lucination domain consists of two items: auditory and
visual hallucinations. Most individuals recorded having no
hallucinations (i.e., median=0, no events), and thus, if an
individual recorded no auditory hallucinations and gave
no information regarding visual hallucinations, then for
the primary analysis the hallucinations domain for that in-
dividual was coded as negative but for the sensitivity ana-
lysis the individual was coded as having at least one
hallucination event.
A secondary analysis was used to compare subjects
who experienced both hallucinations and delusions to
subjects who only experienced delusions. This analysis
examined the frequency and percent of subjects who
experienced delusional domain items, broken down by
item, from the 1996 version of the BRSD [8]. For each
item, subjects with a missing value for that item were
excluded from the analysis. All statistical analyses were
carried out using R 2.11.1 [12,15].
Results
Of the 812 subjects with AD who were originally consid-
ered for this study, 21 (5%) had APOE genotype Ε2Ε4.
Because of the protective effects that have been previ-
ously reported for the APOE*2 allele [15], individuals
with the Ε2Ε4 genotype were excluded from this ana-
lysis, although including them in the analyses produced
similar results to those presented below. An additionalTable 1 Demographics and clinical characteristics of Alzheime
No APOE*4 alleles (n=348) One
Male, frequency (%) 111 (32%) 116
Age at assessment, mean [SD] 78.1 [5.9] 76.2
Duration of illness (years) 3.7 [2.5] 4.2
Education (years) 12.5 [3.1] 12.8
Baseline MMSE 17.5 [5.8] 17.6
Baseline CDR 1.31 [0.69] 1.29
*Chi-square tests for differences in gender by genotype, and ANOVA for differences
Abbreviations: APOE, apolipoprotein E; MMSE, Mini-Mental State Examination; CDR,subject with no neuropsychiatric data available was also
excluded, leaving 790 subjects for the analysis. Table 1
shows that 348 subjects (44%) had no APOE*4 allele,
368 (47%) had one Ε4 allele, and 74 (9%) had two Ε4
alleles. The sample was 33% male and had a mean edu-
cation of 12 years, a mean illness duration of 4 years, a
mean MMSE score of 17.6, and a mean CDR score of
1.29. The mean age at assessment decreased in relation
to the number of APOE*4 alleles subjects possessed,
from 78.1 years (SD 5.9) for those with no APOE*4
alleles to 72.8 years (SD 5.4) for those with two APOE*4
alleles, but otherwise there was no evidence of an associ-
ation between the demographic variables and the num-
ber of APOE*4 alleles.
Table 2 shows the frequency of reported neuropsychi-
atric symptoms in the four domains by number of APOE*4
alleles and the RR of a neuropsychiatric symptoms in a
given domain by one or two APOE*4 alleles versus no
APOE*4 alleles. Of the 790 subjects, 110 (14%) had miss-
ing values for at least one item in the BRSD. The occur-
rence of hallucinations was imputed for 6 (0.8%) subjects,
the occurrence of delusions was imputed for 101 (13%)
subjects, and the occurrence of aberrant motor behavior
was imputed for 9 (1%) subjects; there were no missing
agitation values, so no imputation was necessary for this
domain. Across all 790 subjects, 99 (13%) experienced at
least one occurrence of hallucinations, 540 (68%) experi-
enced an occurrence of delusions, 327 (41%) experienced
an occurrence of agitation, and 426 (54%) experienced an
occurrence of aberrant motor behavior. In comparing sub-
jects with different numbers of APOΕ*4 alleles, the occur-
rence of hallucinations tended to decrease as the number
of APOΕ*4 alleles increased; we found that 53 (15%) sub-
jects with no APOΕ*4 alleles experienced hallucinations,
whereas only 4 (5%) subjects with two APOΕ*4 alleles
experienced hallucinations. These results are illustrated by
the decreasing RRs of hallucinations for one APOΕ*4 allele
(0.71, 95% CI [0.50, 0.97]) and two APOΕ*4 alleles (0.32,
95% CI [0.00, 0.74]) versus no APOΕ*4 alleles after adjust-
ing for age, gender, education, duration of illness, MMSE
score, and CDR score at assessment. A post-hoc analysis
modeling the number of APOE*4 alleles as continuousr’s disease study sample
APOE*4 allele (n=368) Two APOE*4 alleles (n=74) P*
(32%) 32 (43%) .131
[5.8] 72.8 [5.4] <.001
[2.9] 3.9 [2.8] .077
[3.0] 13.1 [2.7] .208
[5.2] 17.5 [5.8] .960
[0.63] 1.24 [0.67] .623
in means across genotype for all other demographic measures.
Clinical Dementia Rating scale; ANOVA, analysis of variance.
Table 2 Frequency of AD subjects with at least one neuropsychiatric symptom in a given domain, and relative risk for
the symptom in that domain by one and two APOΕ *4 alleles versus no APOE*4 allele
Domain No APOΕ *4 allele (n=348) One APOΕ *4 allele (n=368) Two APOΕ *4 alleles (n=74) P*
Hallucinations (2 items)
Frequency (%) 53 (15%) 42 (11%)** 4 (5%)
RR 95% CI 1.00 0.71 (0.50, 0.97) 0.32 (0.00, 0.74) 0.0066
Delusions (10 items)
Frequency (%) 241 (69%) 259 (70%) 40 (54%)
RR 95% CI 1.00 1.05 (0.96, 1.15) 0.87 (0.72, 1.07) 0.160
Agitation (3 items)
Frequency (%) 150 (43%) 147 (40%) 30 (41%)
RR 95% CI 1.00 0.93 (0.79, 1.11) 1.04 (0.77, 1.35) 0.628
Aberrant motor behavior (2 items)
Frequency (%) 196 (56%) 195 (53%) 35 (47%)
RR 95% CI 1.00 0.94 (0.83, 1.07) 0.86 (0.67, 1.08) 0.382
*Generalized linear models of domain on the number of APOΕ *4 alleles (treated as categorical) with log link, and error modeled as Gaussian and with the
following covariates: age, duration of illness, MMSE, CDR, gender, and education.
**2 subjects with 1 APOE 4 allele were missing all hallucination domain data.
Abbreviations: APOE, apolipoprotein E; RR, relative risk; CI, confidence interval; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating scale; BRSD,
Behavioral Rating Scale for Dementia.
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relative decrease in risk of hallucinations of 34% for each
increase in one APOE*4 allele, that is, a relative risk of
0.66, 95%CI (0.49, 0.86). There was no evidence of associa-
tions between the number of APOΕ*4 alleles and the oc-
currence of neuropsychiatric symptoms in the other three
domains. Sensitivity analyses that imputed domains with
missing items to the alternate values yielded similar
results.
Of the 99 subjects who experienced hallucinations, 93
(94%) experienced at least one delusion as well, and of
the 538 subjects who experienced delusions and had
non-missing values for hallucinations, 445 (83%) experi-
enced no hallucinations. The RR of delusions without
hallucinations was 1.14 (95% CI [1.00, 1.29]) for subjectsTable 3 Demographic and clinical characteristics of AD subjec
delusions and hallucinations
Delusions without hallucinations (D) (n
Male, frequency (%) 129 (29%)
APOE ε4 allele frequency
0 APOE ε4 alleles 191 (43%)
1 APOE ε4 allele 218 (49%)
2 APOE ε4 alleles 36 (8%)
Age at assessment, mean (SD) 77.4 (5.8)
Duration of illness (years) 4.1 (2.6)
Education (years) 12.3 (2.9)
Baseline MMSE 17.1 (5.6)
Baseline CDR 1.35 (0.65)
*Chi-square test for gender and allele frequency; t-test for all others.
** 2 subjects missing all hallucination domain data are omitted from this analysis.
Abbreviations: APOE, apolipoprotein E; SD, standard deviation; MMSE, Mini-Mental Swith one APOE*4 allele and 1.00 (95% CI [0.77, 1.29])
for subjects with two APOE*4 alleles versus subjects
with no APOE*4 alleles, in contrast to the RR of halluci-
nations and delusions of 0.71, (95% CI [0.52, 0.97]) and
0.34 (95% CI [0.11, 1.05]) for one and two APOE*4
alleles respectively vs. no alleles. We conducted a sec-
ondary analysis comparing the 445 subjects with delu-
sions and no hallucinations (D) to the 93 subjects with
delusions and hallucinations (D+H). Our findings, sum-
marized in Table 3, show that the D+H group had a sig-
nificantly longer duration of illness, lower MMSE scores,
and higher CDR scores compared to the D group. On
the other hand, there were no significant differences in
gender, age at assessment, and education between the
two groups. Although there was no significant differencets with delusions only compared to subjects with
=445)** Delusions and hallucinations (D+H) (n=93)** P value*
19 (20%) .120
.116
50 (54%)
39 (42%)
4 (4%)
77.7 (6.9) .732
5.0 (3.2) .010
11.8 (2.5) .091
15.4 (6.0) .010
1.75 (0.76) <.001
tate Examination; CDR, Clinical Dementia Rating scale.
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D+H group tended to have lower APOΕ*4 frequencies
than the D group. As Figure 1 illustrates, the D+H group
had significantly higher frequencies for each kind of de-
lusion item than the D group. All comparisons were sta-
tistically significant (paranoid and imposter, P<.05, all
others, P<.01).
Discussion
In this study of AD, we found a significant dose-
dependent relationship between the number of APOE*4
alleles and hallucinations but no association between
APOE*4 and aberrant motor behavior or agitation. We
also found important differences between AD patients
with delusions alone and AD patients who experienced a
co-occurrence of hallucinations and delusions at the
time of baseline assessment. In previous studies, halluci-
nations and delusions were usually combined and cate-
gorized under the broad category of psychosis [16], and
the largest of these studies have shown no association
between APOE*4 and a broad category of psychosis
[5,17]. In a recent genome-wide association study
(GWAS), the odds ratio (OR) was 1.09 for the rs2927438Imposter  n=90
n=444
TV real  n=93
n=443
Abandonment  n=91
n=440
Infidelity  n=53
n=241
Other delusion n=82
n=407
Dead person alive  n=54
n=324
House not home  n=90
n=438
Paranoid  n=91
n=443
Misidentify people  n=92
n=438
Others in house  n=54
n=324
P
0 10 20
Figure 1 Frequency of Delusion Type by Group. Legend: Frequency of
delusions only). This figure demonstrates that the delusions and hallucinati
of delusions compared to the group that experienced delusions only.SNP in the APOE*4 locus that showed the strongest as-
sociation between AD with and without psychosis, but
this association did not reach statistical significance
(p=.306) [5] However, the current study illustrates that
these modest genetic effects might be obscured when
the psychosis phenotype cannot be further subdivided
(e.g., D+H or D alone). The findings of the present study
suggest that psychotic AD subjects who experience hal-
lucinations and delusions may comprise a genetic cat-
egory that is distinct from those subjects who experience
delusions exclusively. These results are partially sup-
ported by several studies that have previously looked at
the possibility of subphenotypes within the broader
category of AD+P [16,18]. In order to analyze this pos-
sible distinction, we classified subjects into two non-
overlapping groups in this study so that each individual
patient belonged to only one group: given that nearly all
of the subjects who experienced hallucinations also
experienced delusions, one of those groups included
subjects who experienced both delusions and hallucina-
tions (D+H) and the other included subjects who experi-
enced D alone. Under the aforementioned two-group
classification model, we found that AD patients with DDelusions + Hallucinations
Delusions only
ercent of Subjects
30 40 50 60 70
specific delusion items by group (delusions and hallucinations vs.
ons group had statistically significant higher frequencies for every kind
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with D alone (i.e., the patients with D+H had a longer
duration of illness, lower baseline MMSE scores, and
higher CDR scores than patients with D alone). Al-
though it is possible that the D+H subjects were simply
farther along in their stage of disease than the D alone
subjects, both groups were in the same stage of demen-
tia (moderate) and the differences in MMSE and CDR
between the two groups were not clinically meaningful.
Interestingly, the D+H subjects also experienced signifi-
cantly higher frequencies of all types of delusions com-
pared to subjects with D alone. Of note, delusions of
misidentification, which are typically associated with de-
mentia with Lewy bodies, were reported in 63% of subjects
with D+H. Unfortunately, we do not have sufficient neuro-
pathological information to determine whether these sub-
jects have Lewy body related and AD pathologies.
After controlling for potential confounders, we con-
sistently found a protective effect of the APOE*4 allele
against D+H. We have previously proposed that there
are potentially two plausible genetic models of AD with
D+H [1]: first, a heterogeneity model in which alleles
predispose or are protective against the development of
AD pathology and subsequent psychosis and, second, a
disease-modifier model in which alleles increase the risk
of psychosis but only in the presence of AD. A recent
GWAS in AD + P found no support for either model, as
there was no genome-wide significant finding for AD +
P when compared to controls (testing model 1) or be-
tween AD with and without psychosis (testing model 2)
[5]. However, even though that GWAS included the lar-
gest available cohort of AD with (n=1299) and without
psychosis (n=735), the power to observe alleles of small
effect was limited. Another explanation for the lack of sig-
nificant GWAS findings may be that the susceptibility to
develop psychosis is due to nongenetic familial factors.
One limitation of this study is that we used proxy report-
ing instead of direct observation to assign the presence or
absence of neuropsychiatric symptoms in each of the four
domains we looked at. Previous studies have shown dis-
crepancies in the accuracy of proxy reporting for assessing
behavioral symptoms of dementia patients when compared
with the use of direct observation [19]. Although direct ob-
servation would have been the preferred method, the size
and nature (comprised entirely of outpatient subjects) of
our observed population made this impractical. Another
limitation is due to missing values that required imputing
the presence or absence of neuropsychiatric symptoms for
a specific domain. However, our main finding involved hal-
lucinations, which required imputation for less than 1% of
the subjects. Furthermore, sensitivity analyses in which
imputed values were set to the alternative value did not
change our findings. Another limitation is that the variabil-
ity observed in the role of ΑPOE*4 with regard to D+Hand AD can at least be partially accounted for by differ-
ences in study design, the size of the cohort examined, the
cognitive and neuropsychiatric tests used, and the tools
and methods by which data were analyzed. In this study,
for example, we noted a large degree of variation between
our subjects in the number of follow-up assessments and
in the time between follow-up assessments, and therefore
we opted to analyze baseline assessments rather than lon-
gitudinal assessments. It is possible, therefore, that our
findings concerning ΑPOE*4 and psychosis may have dif-
fered in a longitudinal data set. As mentioned previously,
we attempted to account for these kinds of differences by
including CDR, MMSE, and other indicators of disease
stage as covariates in our analysis model. Another limita-
tion of our study design, as in any case–control genetic as-
sociation study, is the possibility of spurious associations,
and thus these findings should be replicated in other large
samples and in longitudinal studies.
An important strength of our study is our rigorous clin-
ical assessment of behavioral symptoms. Together with
the size of our sample—one of the largest of its kind—and
our use of AD research subjects who were recruited from
a single geographical site, the comprehensiveness of the
assessments enabled us to differentiate the subtypes of
psychosis. However, the underlying mechanism by which
APOE affects the occurrence of hallucinations and delu-
sions has yet to be elucidated.
Conclusion
In the present study we found that hallucinations were
significantly more likely to occur in subjects with no
APOΕ4 alleles than in subjects with two Ε4 alleles. Fur-
thermore, our findings suggest that in AD the Ε4 allele
is differentially associated with D+H but not delusions
alone. This is consistent with our proposed hypothesis
that distinct psychotic subphenotypes may be associated
with the APOE allele. Future studies should take into ac-
count that the psychotic phenotype in AD patients may
not be homogenous, but consist rather of subphenotypes
of hallucinations and delusions that in turn may have
different genetic associations.
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